Navigation Links
Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Date:9/21/2007

re performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The Company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
2. PromegaExpress Expands Easy Access to Products with New Cabinet
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
6. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Israel , August 3, 2015 ... received the statistical analysis of results from a study which ... BVX-005 phase II trial which took place in 2012, provided ... exist at the time of the study- in particular the ... epidemic in the United States in ...
(Date:8/3/2015)... Minn. , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... neuroblocking therapy to treat obesity, metabolic diseases and other ... has been appointed to the Board of Directors, ... a Class II Director until the 2018 annual meeting ... Ms. McDougal has served in an executive capacity ...
(Date:8/3/2015)... -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) announced ... agreement to develop and commercialize multiple prespecified and undisclosed ... company for premier antibody development and manufacturing companies in ... the terms of the agreement, Sorrento will develop and ... American, European and Japanese market. Each of the mAbs ...
Breaking Medicine Technology:Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4
(Date:8/3/2015)... California (PRWEB) , ... August 03, 2015 , ... Did ... or Orange County looking for exceptional and affordable home care options which A-1 ... services are just a few of the credentials A-1 Home Care Agency ...
(Date:8/2/2015)... ... August 03, 2015 , ... ... attending and exhibiting at the Association for Healthcare Documentation Integrity’s (AHDI) conference being ... are pleased for the opportunity the AHDI conference provides us to interact with ...
(Date:8/2/2015)... ... 03, 2015 , ... For many “would be” entrepreneurs, starting a new business can prove ... afford to start a business.” Neither needs be a major obstacle. , The U.S. ... start a business and be successful. The risks of starting a business can be high ...
(Date:8/2/2015)... ... August 02, 2015 , ... Molecular biologists in New ... indicator for mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... New South Wales tested for Ki67 expression in tissue samples from 42 patients with ...
(Date:8/1/2015)... ... 2015 , ... Back packs can be dangerous? Whaaat?! , Not the danger ... havoc on a kid's spine. With school starting again, most kids will be asking ... you are aware of how to help them prevent injuries by understanding backpack safety. ...
Breaking Medicine News(10 mins):Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2
... HealthDay Reporter , TUESDAY, Sept. 20 (HealthDay News) -- ... children and teens with obsessive-compulsive disorder, new research shows. ... of the Journal of the American Medical Association ... and obsessive-compulsive disorder (OCD). "[If] a child ...
... against methamphetamine and nicotine have been selected to receive ... The two scientists, Dr. Thomas Kosten, of Baylor ... the University of Connecticut, Storrs, will each receive $500,000 ... according to the National Institute on Drug Abuse (NIDA), ...
... , TUESDAY, Sept. 20 (HealthDay News) -- New research ... saved money used for diagnosis and boosted the likelihood that ... follow-up appointments. But there,s a big catch. Researchers ... to $649 on average -- compared to the usual $3,500 ...
... Health (NIH) has awarded nearly $2 million to researchers ... to develop a new class of therapeutics for treating ... project focuses on developing biomaterials capable of capturing certain ... wound sites to enhance tissue regeneration in adults. By ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, Sept. ... breast, babies seem to turn out smarter when nourished with ... two new studies indicate. The studies, done in the ... the journal Pediatrics , found that higher levels of ...
... Foundation,s Discovery Campaign, which seeks to further the growth ... announced a major corporate pledge to that initiative. St. ... Medical, has pledged $100,000 and is a "Pioneer" level ... strengthens SIR Foundation,s Discovery Campaign as it paves the ...
Cached Medicine News:Health News:Adding Psychotherapy to Meds Helps Kids With OCD 2Health News:NIDA Avant-Garde-Medications Development Award winners announced 2Health News:MRI Can Spot Breast Cancer in High-Risk Women: Study 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 3Health News:Can Fatty Acids in Breast Milk or Formula Make Kids Smarter? 2Health News:Can Fatty Acids in Breast Milk or Formula Make Kids Smarter? 3Health News:Society of Interventional Radiology Foundation accepts St. Jude Medical Foundation gift 2
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: